Few FDA concerns for Novo's liraglutide in obesity
This article was originally published in Scrip
Things appear mostly positive for Novo Nordisk going into the 11 September meeting of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) for the review of the company's glucagon-like-peptide (GLP-1) liraglutide for use as a weight-loss medication, with the drug meeting the efficacy standards for that indication and most of its adverse effects already a matter of record.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.